On May 22, 2025, Gyre Therapeutics, Inc. announced that its lead compound, Hydronidone, successfully met its primary endpoint in a Phase 3 trial for liver fibrosis treatment, showing 52.85% of patients had regression in liver fibrosis compared to 29.84% in the placebo group (P=0.0002). The trial involved 248 patients across 39 hospitals in China and demonstrated good safety and tolerability.